5-Month OS Gain in First-Line TNBC: Why TROPION-Breast02 Matters

A five-month improvement in overall survival — in one of the toughest breast cancer populations we treat.

In this clip, Drs. Gradishar and Traina explain why TROPION-Breast02 is practice-changing, particularly for patients with refractory disease, prior chemotherapy exposure, and limited treatment options.

They also discuss why allowing stable brain metastases and no restriction on disease-free interval makes these results even more meaningful.